[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,624
Citations 0
This Week in JAMA
April 18, 2012

This Week in JAMA

JAMA. 2012;307(15):1555. doi:10.1001/jama.2012.470


Edited by Robert M. Golub, MD, and Phil B. Fontanarosa, MD, MBA

Bevacizumab-carboplatin-paclitaxel has been an approved treatment regimen for advanced non–small cell lung cancer since 2006. In a retrospective cohort study of 4168 Medicare beneficiaries with advanced non–small cell lung cancer, Zhu and colleagues found that the addition of bevacizumab to carboplatin-paclitaxel therapy was not associated with improved survival.


In an analysis of data from 223 475 adults with major trauma admitted to level I or level II trauma centers, Galvagno and colleagues found that survival to hospital discharge was improved among patients transported by helicopter emergency medical services (EMS) compared with ground EMS transport.